Interferons in relapsing remitting multiple sclerosis

[...]sustained change in the EDSS score at 2 years was analysed on less than 40% of randomised patients, putting into doubt the MSCRG claim that the probabilities of sustained progression were 34.9% for placebo and 21.9% for interferon. [...]as we noted in our original paper, 50% of Avonex-treated p...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Lancet (British edition) 2003-05, Vol.361 (9371), p.1824-1825
Hauptverfasser:	Filippini, Graziella, Munari, Luca, Ebers, George C, D'Amico, Roberto, Rice, George PA
Format:	Artikel
Sprache:	eng
Schlagworte:	Interferon Multiple sclerosis Patients
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!